Given the aberrant expression of JMJD2A and its involvement in the Akt-mTOR pathway, which aligns with our research focus on the effects of TB on glioma cell cycle regulation, we aimed to intensively study methylstat for its potential as a glioma therapeutic. This evidence concerns the gene KDM4A and glioma.